Cyclooxygenase-2 inhibitors: promise or peril?
The discovery of two isoforms of the cyclooxygenase enzyme, COX-1 and COX-2, and the development of COX-2-specific inhibitors as anti-inflammatories and analgesics have offered great promise that the therapeutic benefits of NSAIDs could be optimized through inhibition of COX-2, while minimizing thei...
Saved in:
Main Authors: | Laurel J. Mengle-Gaw (Author), Benjamin D. Schwartz (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2002-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Perils and Promises of Public Scholarship
by: Michael Rifenburg, et al.
Published: (2022) -
Universal health care in Bangladesh-promises and perils
by: Allayne M Adams, et al.
Published: (2018) -
Promises and perils of the FDA's over-the-counter naloxone reclassification
by: David T. Zhu, et al.
Published: (2023) -
Big Data Analytics and the Struggle for Equity in Health Care: The Promise and Perils
Published: (2020) -
Reduction in cancer risk by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors
by: Harris RE, et al.
Published: (2012)